Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Aqupla (nedaplatin)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(6)
News
Trials
Company:
Simcere
Drug class:
DNA synthesis inhibitor
Related drugs:
‹
cisplatin (330)
gemcitabine (181)
temozolomide (114)
cytarabine (99)
oxaliplatin (57)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
cisplatin (330)
gemcitabine (181)
temozolomide (114)
cytarabine (99)
oxaliplatin (57)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Nasopharyngeal Carcinoma
No biomarker
Nasopharyngeal Carcinoma
nedaplatin
Sensitive: A2 - Guideline
nedaplatin
Sensitive
:
A2
nedaplatin
Sensitive: A2 - Guideline
nedaplatin
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
nedaplatin
Sensitive: C3 – Early Trials
nedaplatin
Sensitive
:
C3
nedaplatin
Sensitive: C3 – Early Trials
nedaplatin
Sensitive
:
C3
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
nedaplatin
Resistant: C3 – Early Trials
nedaplatin
Resistant
:
C3
nedaplatin
Resistant: C3 – Early Trials
nedaplatin
Resistant
:
C3
BRCA1 mutation
Ovarian Cancer
BRCA1 mutation
Ovarian Cancer
nedaplatin
Resistant: C3 – Early Trials
nedaplatin
Resistant
:
C3
nedaplatin
Resistant: C3 – Early Trials
nedaplatin
Resistant
:
C3
FOXP3 overexpression
Esophageal Squamous Cell Carcinoma
FOXP3 overexpression
Esophageal Squamous Cell Carcinoma
nedaplatin
Sensitive: C3 – Early Trials
nedaplatin
Sensitive
:
C3
nedaplatin
Sensitive: C3 – Early Trials
nedaplatin
Sensitive
:
C3
SLFN11 expression
Acute Lymphocytic Leukemia
SLFN11 expression
Acute Lymphocytic Leukemia
nedaplatin
Sensitive: D – Preclinical
nedaplatin
Sensitive
:
D
nedaplatin
Sensitive: D – Preclinical
nedaplatin
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.